Pipeline
Product Discovery and Development
Our pipeline shows our priority programs and their respective development plans.
pipeline
Projects identified, prioritized, and progressing through drug discovery and development
Shown below are six programs entered into our pipeline. Additional targets are already identified for future pipeline entry or partnering. Potentially responsive patient subgroups within each indication are being defined for each project.
LEAD IDENTIFICATION
IND
CANDIDATE SELECTION
PHASE 1
IMB1001: CD, SLE
INDICATION: CD, SLE
MOA: NK cell down-regulator and Treg up-regulator
MODALITY: Humanized mAb
IMB1002: UC, SLE
INDICATION: UC, SLE
MOA: Cytokine modulator
MODALITY: Bi-specific Ab
IMB1003: CD, SLE
INDICATION: CD, SLE
MOA: B and NK cell down-regulator
MODALITY: Mutein
IMB1004: SLE, CD, UC
INDICATION: SLE, CD, UC
MOA: T and NK cell down-regulator
MODALITY: mAb
IMB1005: UC, other
INDICATION: UC, other
MOA: MHC-mediated antigen processing & presentation
MODALITY: mAb
IMB1006: TBD
INDICATION: TBD
MOA: Down-regulator of T-cell activation
MODALITY: mAb
CASE STUDY
We are pioneering class discovery for IMID precision medicines
1
Using IMIDomics molecular data, we identified new SLE classes.
2
Key clinical features are associated with each specific SLE class.
3
Differential enrichment is consistent with our understanding of the disease.
4
Using ML, build models that precisely predict classes in new patients.
5
We then precisely map our pipeline programs onto patient classes that enrich for drug responders.
Five classes of SLE defined by IMIDOMICS
Class-specific clinical features identified
Demonstrated drug targets
ROBUST CLASS PREDICTORS ARE REPLICATED
BIOMARKER TO ENRICH FOR DRUG RESPONSE
Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases
Five classes of SLE defined by IMIDOMICS
Class-specific clinical features identified
Demonstrated drug targets
ROBUST CLASS PREDICTORS ARE REPLICATED
BIOMARKER TO ENRICH FOR DRUG RESPONSE
